Backed by Novartis AG, Viamet Sets Terms for $86 Million IPO

Published: May 04, 2016

Viamet Pharmaceuticals Holdings, a biotech developing metal-binding protein therapeutics to treat fungal diseases, announced terms for its IPO on Tuesday.

The Durham, NC-based company plans to raise $86 million by offering 5.7 million shares at a price range of $14 to $16. Insiders intend to purchase $40 million worth of shares in the offering. At the midpoint of the proposed range, Viamet Pharmaceuticals Holdings would command a fully diluted market value of $389 million.

Back to news